← All trials
NCT06890143
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Mar 31, 2027
- First posted
- Mar 21, 2025
- Last posted
- Jun 15, 2025
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Maternal and Child Health Care Hospital of Hainan ProvinceCollaborator
- Zhejiang UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Henan Medical UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Xian Children's HospitalCollaborator
- Kunming Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Wuhan Children's HospitalCollaborator
- Fudan UniversityOfficial
- Sun Yat-Sen UniversityCollaborator
- Capital Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Guiyang Maternity and Child Health Care HospitalCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.